UNSPSC 51101648: Clefamide

This classification denotes an antiprotozoal agent with the molecular formula C17H16Cl2N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4AZ2V8K4EK, chemically known as 2,2-dichloro-n-(2-hydroxyethyl)-n-(p-(p-nitrophenoxy)benzyl)acetamide but generally known as clefamide, which bears US NIH Compound Identifier 71819. European Medicines Agency schedules Clefamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06647MIG.

UNSPSC 51101648 Clefamide is a Commodity code that in practice covers pharmaceutical products and medical supplies procurement by state and local health agencies, though the recent solicitations tagged to this code reflect a broader pharmaceutical and health-supply buying pattern than the code name alone suggests. State and local governments use this code to buy naloxone and drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and emergency medical supplies including respiratory equipment, cardiac monitoring devices, endotracheal tubes, and medical consumables. Issuing bodies span state health departments (Texas Health and Human Services Commission), county health agencies (Seminole County, Florida), city fire and rescue departments (City of Tampa Fire Department), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The buying pattern shows health and safety agencies—particularly emergency response and public health divisions—as primary users.

Recent activity is concentrated in Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The City of Tampa issued an IFB in March 2026 for medical and first aid supplies (169 line items) for the Tampa Fire Department Rescue Division, designated as a sheltered-market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount and an estimated contract value of $700,000, due March 13, 2026. The Texas Health and Human Services Commission issued an RFI in April 2026 regarding direct-to-manufacturer prescription programs under a Therapeutic Pharmacy Initiative. The Minnesota Department of Administration issued an RFP through MMCAP in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026.